DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Gastro Esophageal Reflux Disease (GERD) Drug and Devices Market - Analysis and Forecast 2017-2023 (Focus on Device Type, Drug Type, Market Share Analysis, Patent Landscape and Country Analysis)" report to their offering.
The global market is expected to reach $5.56 billion by 2023. With the advent of generics & OTC products the growth in GERD drugs market has decreased. The absence of patent protected & new regulatory approved medicines are the restraints for the growth of this market. The global GERD drugs market has a low growth potential in future and will account to $5.38 billion by 2023.
The increasing demand of medical devices have led various companies to focus on new product developments and innovations, and further carry out other market developments as well. In this market, major companies are adopting partnerships and collaboration strategies to strengthen their position among other players.
Due to side effects of drugs on long term use, patients who fail to respond to medication & the availability of new technology, the device market is set to grow in future. The devices market shows a high growth potential with a CAGR of 15.3% from 2017 to 2023.
The key companies profiled in the report are AstraZeneca, Johnson & Johnson, Takeda Pharmaceuticals, Teva Pharmaceuticals, Torax Medical, Medigus, Medtronic, Eisai Inc., Ironwood Pharmaceuticals, GlaxoSmithKline, and Endogastric Solutions, among others.
Key Topics Covered:
1 Report Scope & Methodology
2 Market Overview
4 Drug Pipeline Analysis
5 Competitive Landscape
6 Industry Analysis
7 Global GERD Drug Market by Route of Administration, 2016-2023 (Qualitative)
8 Global GERD Drug Market by Dosage Form, 2016-2023 (Qualitative)
9 Global GERD Market by Drug Type, 2016-2023
10 Global GERD Market by Device Type, 2016-2023
11 Global GERD Drug and Devices Market by Region, 2016-2023
12 Company Profiles
- AstraZeneca PLC
- Boston Scientific Corporation
- Cempra Inc.
- Eisai Co., Ltd.
- EndoGastric Solutions Inc.
- EndoStim Inc.
- GlaxoSmithKline Plc
- Ironwood Pharmaceuticals, Inc.
- Jeil pharmaceutical Co. Ltd.
- Johnson & Johnson
- Mederi Therapeutics Inc.
- Medigus Ltd.
- Medtronic Inc.
- Merck & CO., Inc.
- Novartis AG
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceuticals Industries Limited.
- Torax Medical
- Valeant Pharmaceuticals International, Inc.
For more information about this report visit http://www.researchandmarkets.com/research/thst25/global_gastro